Citius Oncology Inc. (NASDAQ: CTOR) announced that an investigator-initiated study of its drug LYMPHIR in combination with pembrolizumab has been ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE